Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | UBE2N | P61088 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407652 | 0.88 | L3MBTL1 (0.32) | L3MBTL1KDM4EALDH1A1TDP1KMT2A | |
| SCHEMBL6336269 | 0.86 | SMN1; SMN2 (0.39) | L3MBTL1ALDH1A1TDP1MAPTATM | |
| SCHEMBL6408653 | 0.78 | PI4KB (0.40) | L3MBTL1KDM4EBRAFMAPTATM | |
| SCHEMBL6336973 | 0.74 | CDK2 (0.41) | L3MBTL1KDM4EATMKMT2ALMNA | |
| SCHEMBL6533769 | 0.70 | PI4KB (0.39) | ALDH1A1ATMKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6503511 | 0.68 | HPGD (0.40) | L3MBTL1ALDH1A1KMT2ALMNAPOLB | |
| SCHEMBL6332610 | 0.68 | PKM (0.39) | L3MBTL1KDM4EALDH1A1BRAFATM | |
| SCHEMBL6332611 | 0.68 | PKM (0.39) | L3MBTL1KDM4EALDH1A1BRAFATM | |
| SCHEMBL6402827 | 0.67 | PKM (0.37) | L3MBTL1ALDH1A1BRAFKMT2ALMNA | |
| SCHEMBL6407647 | 0.66 | PI4KB (0.34) | L3MBTL1KDM4EALDH1A1TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969713-B2 | Piperidine and piperazine acetamide derivatives | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | claimed |
| EP-1242427-B1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-08-13 | — | — | EP | claimed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| US-6969713-B2 | Piperidine and piperazine acetamide derivatives | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| EP-1242427-B1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-08-13 | — | — | EP | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | CYP3A5, IL5, ABCC5 | PSMD14 533/4885APAF1 1189/4885UBE2N 2301/4885 |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | PSMD14 997/4885APAF1 1002/4885UBE2N 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.